57,526 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by World Investment Advisors LLC

World Investment Advisors LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 57,526 shares of the biopharmaceutical company's stock, valued at approximately $3,293,000.

Other hedge funds have also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Halozyme Therapeutics by 15.2% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 11,771 shares of the biopharmaceutical company's stock worth $616,000 after acquiring an additional 1,554 shares during the period. Envestnet Portfolio Solutions Inc. increased its position in Halozyme Therapeutics by 21.3% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 11,467 shares of the biopharmaceutical company's stock worth $600,000 after purchasing an additional 2,016 shares during the period. Miracle Mile Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $228,000. Boston Trust Walden Corp acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $23,211,000. Finally, Hoylecohen LLC purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at approximately $209,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HALO has been the subject of several research analyst reports. JPMorgan Chase & Co. cut Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and increased their price objective for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. JMP Securities increased their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a report on Friday, November 1st. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and boosted their price objective for the stock from $58.00 to $62.00 in a report on Monday, October 7th. HC Wainwright reaffirmed a "buy" rating and issued a $68.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, November 20th. Finally, Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $61.11.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $56.34, for a total transaction of $563,400.00. Following the transaction, the chief executive officer now owns 676,744 shares of the company's stock, valued at $38,127,756.96. This represents a 1.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. In the last quarter, insiders sold 40,000 shares of company stock worth $2,242,100. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO traded up $0.17 during trading on Friday, reaching $48.00. The company had a trading volume of 932,105 shares, compared to its average volume of 1,358,199. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53. The stock has a 50-day moving average price of $51.43 and a two-hundred day moving average price of $53.92. The stock has a market capitalization of $6.11 billion, a PE ratio of 15.89, a price-to-earnings-growth ratio of 0.43 and a beta of 1.23.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.